Shoulder Innovations' Revenue Jumps 44%, But Losses Widen Post-IPO

TL;DR

**Shoulder Innovations is burning cash despite strong revenue growth; the IPO bought them time, but profitability is still a distant dream.**

AI Summary

Shoulder Innovations, Inc. (SI) reported a significant increase in net revenue for the nine months ended September 30, 2025, reaching $32.901 million, up from $22.898 million in the same period of 2024, representing a 43.7% increase. Despite this revenue growth, the company's net loss widened substantially to $32.587 million for the nine months ended September 30, 2025, compared to a net loss of $11.827 million in the prior year, primarily due to increased operating expenses and significant 'Other Expense' items. Selling, General and Administrative Expenses rose to $38.428 million from $25.368 million, and Research and Development Expenses increased to $4.514 million from $3.322 million. A major contributor to the increased loss was a $11.719 million change in fair value of Series E purchase option and a $2.217 million change in fair value of convertible notes. The company completed an IPO, converting all preferred stock to common stock and issuing 5,000,000 shares, resulting in a substantial increase in cash and cash equivalents to $54.934 million from $6.123 million at December 31, 2024, and marketable securities to $82.354 million from $8.921 million. Total assets surged to $177.762 million from $43.080 million, reflecting the IPO proceeds, while long-term debt remained relatively stable at $14.848 million.

Why It Matters

This filing reveals a company in a critical growth phase, leveraging an IPO to significantly bolster its cash position to $54.934 million and marketable securities to $82.354 million. While revenue growth of 43.7% to $32.901 million is positive for investors, the widening net loss to $32.587 million, driven by operational costs and fair value adjustments, signals ongoing profitability challenges. Employees might see job security from the increased capital, but customers and the broader market will watch if SI can translate its expanded financial runway into sustained innovation and market share against competitors in the medical device space. The competitive landscape in orthopedic devices is intense, and SI's ability to convert its cash into market acceptance and profitability will be key.

Risk Assessment

Risk Level: high — The company reported a net loss of $32.587 million for the nine months ended September 30, 2025, a significant increase from $11.827 million in the prior year, indicating a substantial cash burn. Despite a cash and cash equivalents balance of $54.934 million and marketable securities of $82.354 million post-IPO, the 'Risk Factors Summary' explicitly states, 'We are an early-stage company with a history of significant net losses, we expect to incur operating losses in the future and we may not be able to achieve or sustain profitability.'

Analyst Insight

Investors should exercise caution and closely monitor Shoulder Innovations' next few quarters for signs of improved operational efficiency and a clear path to profitability. While the IPO provided a significant cash infusion, the widening net loss suggests that capital is being deployed rapidly without immediate returns. Consider this a high-risk, high-reward play, and only allocate capital that you are prepared to lose.

Financial Highlights

revenue

$32.901M

total Assets

$177.762M

total Debt

$14.848M

net Income

-$32.587M

cash Position

$54.934M

revenue Growth

+43.7%

Key Numbers

• $32.901M — Net Revenue (Increased 43.7% from $22.898M year-over-year for nine months ended Sep 30, 2025)
• $32.587M — Net Loss (Widened from $11.827M year-over-year for nine months ended Sep 30, 2025)
• $54.934M — Cash and Cash Equivalents (Increased significantly from $6.123M at Dec 31, 2024, post-IPO)
• $82.354M — Marketable Securities (Increased from $8.921M at Dec 31, 2024, post-IPO)
• $177.762M — Total Assets (Increased from $43.080M at Dec 31, 2024, reflecting IPO proceeds)
• $11.719M — Change in fair value of Series E purchase option (Major contributor to increased 'Other Expense' and net loss)
• 20,601,684 — Common Stock Shares Outstanding (As of November 5, 2025, reflecting IPO and conversions)
• $14.848M — Long-Term Debt (Remained relatively stable compared to $14.658M at Dec 31, 2024)

Key Players & Entities

• SHOULDER INNOVATIONS, INC. (company) — Registrant as specified in its charter
• SEC (regulator) — Securities and Exchange Commission
• $32.901 million (dollar_amount) — Net Revenue for nine months ended September 30, 2025
• $22.898 million (dollar_amount) — Net Revenue for nine months ended September 30, 2024
• $32.587 million (dollar_amount) — Net Loss for nine months ended September 30, 2025
• $11.827 million (dollar_amount) — Net Loss for nine months ended September 30, 2024
• $54.934 million (dollar_amount) — Cash and cash equivalents as of September 30, 2025
• $82.354 million (dollar_amount) — Marketable securities as of September 30, 2025
• $11.719 million (dollar_amount) — Change in fair value of Series E purchase option
• The New York Stock Exchange (regulator) — Exchange where Common Stock is registered

FAQ

Risk Factors

• Volatility in Fair Value of Financial Instruments [high — financial]: The company experienced significant fluctuations in the fair value of its Series E purchase option ($11.719 million) and convertible notes ($2.217 million) in the nine months ended September 30, 2025. These changes substantially increased the net loss, highlighting a financial risk associated with the valuation of these instruments.
• Increased Operating Expenses [high — operational]: Selling, General and Administrative Expenses grew by 51.4% to $38.428 million, and Research and Development Expenses increased by 35.9% to $4.514 million for the nine months ended September 30, 2025. This rapid escalation in operating costs outpaced revenue growth, contributing to a wider net loss.
• Dependence on IPO Proceeds [medium — financial]: The company's cash position dramatically increased from $6.123 million to $54.934 million due to the IPO. While this provides liquidity, it indicates a reliance on capital markets for funding, and future funding needs could be a risk if market conditions are unfavorable.
• Competitive Market for Shoulder Innovations [medium — market]: The orthopedic device market, particularly for shoulder implants, is highly competitive with established players and ongoing innovation. SI faces risks related to market adoption, technological obsolescence, and pricing pressures from competitors.
• Regulatory Approval and Compliance [medium — regulatory]: As a medical device company, SI is subject to stringent regulatory requirements from bodies like the FDA. Delays in product approval, post-market surveillance, or changes in regulations can significantly impact product launches and market access.
• Continued Net Losses [high — financial]: Despite significant revenue growth, the company continues to report substantial net losses, widening to $32.587 million for the nine months ended September 30, 2025. Sustained losses could impact the company's ability to fund operations and future growth.

Industry Context

The orthopedic device market, particularly for shoulder implants, is characterized by significant innovation and a competitive landscape dominated by large, established players. Companies like Shoulder Innovations, Inc. must navigate complex regulatory pathways (e.g., FDA approval) and demonstrate clear clinical and economic benefits to gain market share. Trends include the development of less invasive surgical techniques and patient-specific implants.

Regulatory Implications

As a medical device manufacturer, Shoulder Innovations, Inc. is subject to rigorous oversight by regulatory bodies such as the FDA. Compliance with quality system regulations, obtaining pre-market approval or clearance for new devices, and adhering to post-market surveillance requirements are critical. Any failure to comply can lead to product recalls, fines, or market withdrawal, posing significant operational and financial risks.

What Investors Should Do

1. [object Object]
2. [object Object]
3. [object Object]
4. [object Object]

Key Dates

• 2025-09-30: Nine months ended September 30, 2025 — Reported significant revenue growth of 43.7% but also a substantial widening of net loss due to increased operating expenses and financial instrument fair value changes.
• 2025-12-31: As of December 31, 2024 — Company had significantly lower cash ($6.123M) and marketable securities ($8.921M) and total assets ($43.080M) prior to the IPO.
• 2025-11-05: Common Stock Shares Outstanding as of November 5, 2025 — Indicates the post-IPO share structure, with 20,601,684 shares outstanding.

Glossary

Series E purchase option

An option related to the Series E preferred stock financing round, whose fair value changes can impact the company's net income or loss. (A significant factor contributing to the company's increased 'Other Expense' and net loss in the period.)

Convertible notes

Debt instruments that can be converted into equity under certain conditions, often used by startups for funding. (Changes in their fair value directly affected the company's net loss, indicating financial complexity.)

IPO

Initial Public Offering, the process by which a private company becomes public by selling shares to the public for the first time. (The IPO significantly boosted the company's cash reserves and total assets, transforming its financial position.)

Accumulated deficit

The cumulative net losses of a company since its inception, offset by any profits. (SI has a substantial accumulated deficit of $89.628 million as of September 30, 2025, reflecting its history of losses.)

Fair value

The estimated market price of an asset or liability, determined by current market conditions. (Fluctuations in the fair value of financial instruments are a key driver of the company's reported net loss.)

Year-Over-Year Comparison

Compared to the prior year's nine-month period, Shoulder Innovations, Inc. has demonstrated impressive revenue growth of 43.7%, reaching $32.901 million. However, this top-line expansion has been overshadowed by a significant widening of the net loss, which more than doubled from $11.827 million to $32.587 million. This increased loss is primarily driven by a substantial rise in operating expenses, particularly Selling, General and Administrative costs, and non-operational 'Other Expense' items related to the fair value changes of financial instruments. The company's balance sheet has been dramatically strengthened by the IPO, with cash and cash equivalents soaring from $6.123 million to $54.934 million and total assets increasing from $43.080 million to $177.762 million.

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share SI The New York Stock Exchang

Filing Documents

• si-20250930.htm (10-Q) — 1488KB
• ex-311q32025.htm (EX-31.1) — 9KB
• ex-312q32025.htm (EX-31.2) — 9KB
• ex-321q32025.htm (EX-32.1) — 6KB
• ex-322q32025.htm (EX-32.2) — 6KB
• 0001699350-25-000017.txt ( ) — 6040KB
• si-20250930.xsd (EX-101.SCH) — 31KB
• si-20250930_cal.xml (EX-101.CAL) — 52KB
• si-20250930_def.xml (EX-101.DEF) — 225KB
• si-20250930_lab.xml (EX-101.LAB) — 479KB
• si-20250930_pre.xml (EX-101.PRE) — 350KB
• si-20250930_htm.xml (XML) — 680KB

- Financial Information

Part I - Financial Information

Financial Statements (unaudited)

Item 1. Financial Statements (unaudited) 5 Condensed Balance Sheets 5 Condensed Statements of Operations and Comprehensive Loss 7 Condensed Statements of Changes in Convertible Preferred Stock and Stockholder's Equity ( D e f i c i t ) 8 Condensed Statements of Cash Flows 10 Notes to the Unaudited Condensed Financial Statements 12

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 20

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 31

Controls and Procedures

Item 4. Controls and Procedures 32

- Other Information

Part II - Other Information

Legal Proceedings

Item 1. Legal Proceedings 33

Risk Factors

Item 1A. Risk Factors 33

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 82

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 83

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 83

Other Information

Item 5. Other Information 83

Exhibits

Item 6. Exhibits 83

Signatures

Signatures 85 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q for the quarter ended September 30, 2025 contains forward-looking statements. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q, including but not limited to statements regarding our future results of operations and financial condition, our business plans and strategy, the potential market size, market trends and growth opportunities for our products, macroeconomic and geopolitical conditions, and the sufficiency of our cash balances, working capital and cash generated from our operations, investing and financing activities for future liquidity and capital resource needs, may be forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "will," "would," "should," "expects," "plans," "anticipates," "could," "intends," "targets," "projects," " contemplates," "believes," "estimates," "forecasts," "predicts," "potential" or "continue" or the negative of these terms or other similar expressions that convey uncertainty of future events or outcomes, although not all forward-looking statements contain these identifying words. The forward-looking statements in this Quarterly Report on Form 10-Q are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results,

Financial Information

Part I. Financial Information

Financial Statements

Item 1. Financial Statements September 30, 2025 December 31, 2024 Assets Current Assets Cash and cash equivalents $ 54,934 $ 6,123 Marketable securities 82,354 8,921 Trade accounts receivable, net of allowance for credit losses 7,079 5,122 Inventories, net 19,358 13,955 Prepaid expenses 1,710 431 Other current assets 1,175 573 Total Current Assets 166,610 35,125 Property and equipment, net 10,846 7,487 Operating lease right-of-use asset 131 68 Intangible assets, net 175 400 Total Assets 177,762 43,080 Liabilities, Convertible Preferred Stock, and Stockholders' Equity (Deficit) Current Liabilities Accounts payable ($ 1,033 and $ 813 to related parties, respectively) 8,877 4,860 Current operating lease obligations 70 47 Accrued liabilities 6,072 2,740 Total Current Liabilities 15,019 7,647 Long-Term Liabilities Preferred stock warrant liability — 970 Long-term debt 14,848 14,658 Other long-term liabilities 63 25 Total Long-Term Liabilities 14,911 15,653 Total Liabilities 29,930 23,300 Commitments and contingencies (note 8) Convertible Preferred Stock Series Seed, $ 0.001 par value, no and 16,840,400 shares authorized, and no and 15,851,401 issued and outstanding as of September 30, 2025 and December 31, 2024, respectively — 1,337 Series A, $ 0.001 par value, no and 22,399,370 shares authorized, and no and 22,399,370 issued and outstanding as of September 30, 2025 and December 31, 2024, respectively — 5,600 Series B, $ 0.001 par value, no and 6,913,964 shares authorized, and no and 5,913,964 issued and outstanding as of September 30, 2025 and December 31, 2024, respectively — 2,200 Series C, $ 0.001 par value, no and 50,116,284 shares authorized, and no and 50,116,284 issued and outstanding as of September 30, 2025 and December 31, 2024, respectively — 21,550 Series D, $ 0.001 par value, no and 83,403,626 shares authorized, and no and 80,909,169 issued and outstanding as of September 30, 2025 and December 31, 2024, respectively